Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Short term Debt (2017 - 2026)

Aytu Biopharma has reported Short term Debt over the past 14 years, most recently at $1.9 million for Q4 2025.

  • Quarterly Short term Debt fell 53.71% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, down 53.71% year-over-year, with the annual reading at $9.1 million for FY2025, 388.05% up from the prior year.
  • Short term Debt was $1.9 million for Q4 2025 at Aytu Biopharma, down from $14.9 million in the prior quarter.
  • Over five years, Short term Debt peaked at $16.7 million in Q2 2021 and troughed at $90000.0 in Q4 2022.
  • The 5-year median for Short term Debt is $1.9 million (2024), against an average of $4.4 million.
  • Year-over-year, Short term Debt crashed 96.55% in 2021 and then soared 3205.0% in 2023.
  • A 5-year view of Short term Debt shows it stood at $1.2 million in 2021, then crashed by 92.54% to $90000.0 in 2022, then skyrocketed by 1040.0% to $1.0 million in 2023, then soared by 291.03% to $4.0 million in 2024, then tumbled by 53.71% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Short term Debt are $1.9 million (Q4 2025), $14.9 million (Q3 2025), and $9.1 million (Q2 2025).